Characterization of the Rifamycin-Degrading Monooxygenase From Rifamycin Producers Implicating Its Involvement in Saliniketal Biosynthesis

by Xiao-Fu Zheng, Xin-Qiang Liu, Shu-Ya Peng, Qiang Zhou, Bin Xu, Hua Yuan, Hua Yuan, Gong-Li Tang
Published 2020-06-01

Deciphering the late steps of rifamycin biosynthesis

by Feifei Qi, Chao Lei, Fengwei Li, Xingwang Zhang, Jin Wang, Wei Zhang, Zhen Fan, Weichao Li, Gong-Li Tang, Youli Xiao, Guoping Zhao, Shengying Li
Published 2018-06-01

Generation of Tetracycline and Rifamycin Resistant Chlamydia Suis Recombinants

by Hanna Marti, Sankhya Bommana, Timothy D. Read, Timothy D. Read, Theresa Pesch, Barbara Prähauser, Deborah Dean, Deborah Dean, Deborah Dean, Nicole Borel
Published 2021-06-01

Rifamycin O, An Alternative Anti-<i>Mycobacterium abscessus</i> Agent

by Bui Thi Bich Hanh, June-Woo Park, Tae Ho Kim, Jae-Sung Kim, Chul-Su Yang, Kiseok Jang, Jinsheng Cui, Dong-Chan Oh, Jichan Jang
Published 2020-03-01

Topological modeling of antimycobacterial activity of 3-formyl rifamycin SV derivatives

by Omar Deeb, Jyoti Singh, R.G. Varma, Padmakar V. Khadikar
Published 2007-08-01

Intralesional 8.33% Rifamycin infiltration; New treatment for cutaneous leishmaniasis

by Nameer K. Al-Sudany, Yousif J. Ali
Published 2016-01-01

Report concerning the colaborative study for establish of reference standard eficacity of Rifamycin

by Simona Sturzu, Daniela Tîrsînoagă, Ioana Tihulcă, Mariana Dumitrache, Alina Drăghici, Valentina Năstase
Published 2015-12-01

A Genetic Study of Resistance to Rifampin, Rifamycin SV, Streptovaricin, And Streptolydigin in Staphylococcus Aureus

by Morrow, Terry O.
Published 1973

Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-Analysis.

by Neesha Rockwood, Leila H Abdullahi, Robert J Wilkinson, Graeme Meintjes
Published 2015-01-01

Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism

by James Peek, Mirjana Lilic, Daniel Montiel, Aleksandr Milshteyn, Ian Woodworth, John B. Biggins, Melinda A. Ternei, Paula Y. Calle, Michael Danziger, Thulasi Warrier, Kohta Saito, Nathaniel Braffman, Allison Fay, Michael S. Glickman, Seth A. Darst, Elizabeth A. Campbell, Sean F. Brady
Published 2018-10-01

A feedback regulatory model for RifQ-mediated repression of rifamycin export in Amycolatopsis mediterranei

by Chao Lei, Jingzhi Wang, Yuanyuan Liu, Xinqiang Liu, Guoping Zhao, Jin Wang
Published 2018-01-01

Correction: Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-Analysis.

by PLOS ONE Staff
Published 2015-01-01

Comparison of Rifamycins for Efficacy Against Mycobacterium avium Complex and Resistance Emergence in the Hollow Fiber Model System

by Gunavanthi D. Boorgula, Laxmi U. M. R. Jakkula, Tawanda Gumbo, Bockgie Jung, Shashikant Srivastava, Shashikant Srivastava
Published 2021-04-01

8-Deoxy-Rifamycin Derivatives from <i>Amycolatopsis mediterranei</i> S699 <i>ΔrifT</i> Strain

by Feng Ye, Yanrong Shi, Shengliang Zhao, Zhiying Li, Haoxin Wang, Chunhua Lu, Yuemao Shen
Published 2020-09-01

Pharmacokinetic Drug Interactions of Antimicrobial Drugs: A Systematic Review on Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams

by Jan-Willem C. Alffenaar, Arianna D. Pranger, Mathieu S. Bolhuis, Jos G. W. Kosterink, Prashant N. Panday
Published 2011-11-01

Clinical and pharmacological hallmarks of rifapentine&rsquo;s use in diabetes patients with active and latent tuberculosis: do we know enough?

by Zheng C, Hu X, Zhao L, Hu M, Gao F
Published 2017-10-01

Etymologia: Rifampin

by Ronnie Henry
Published 2018-03-01

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?

by Carolina Arana Stanis Schmaltz, Fernanda de Oliveira Demitto, Flavia Marinho Sant’Anna, Valeria Cavalcanti Rolla
Published 2019-02-01

Improved Rifamycin B Production by Nocardia mediterranei MTCC 14 under Solid-State Fermentation through Process Optimization

by Basavaraj M. Vastrad, Shivayogeshwar E. Neelagund, Sudhir R. Iiger, Ajeet M. Godbole, Venkatrao Kulkarni
Published 2014-01-01

Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.

by Paul J Converse, Deepak V Almeida, Rokeya Tasneen, Vikram Saini, Sandeep Tyagi, Nicole C Ammerman, Si-Yang Li, Nicole M Anders, Michelle A Rudek, Jacques H Grosset, Eric L Nuermberger
Published 2018-08-01